Four years after Emily Whitehead was treated with chimeric antigen receptor T (CAR-T) cell therapy for acute lymphoblastic leukemia (ALL), she remains cancer free. With these striking clinical results, the CAR-T field has expanded rapidly over the past five years.
At Nelsen Biomedical, we teamed up with Cell and Gene Therapy Insights to publish a peer-reviewed article, Unlocking the Therapeutic and Commercial Potential of CAR-T Technology. Here we review the current state of CAR-T therapeutics, from improvements in CAR-T technology at the bench to clinical results at the bedside, and business growth from investment landscape to initial public offerings and future applications.
We provide insight from key investors in discussing the remaining barriers to successful commercialization of CAR-T technology. For more on the strategic partnerships, acquisition and licensing deals done in this space see our CAR-T Deal Review.